文章核心观点 - Verve Therapeutics公司被指控在2022年8月9日至2024年4月1日期间存在证券欺诈行为 [1][2] - 该公司未充分披露Heart-1 Phase 1b临床试验停止的具体情况 [2] - 该公司夸大了其专有脂质纳米颗粒递送系统的潜在利益 [2] 公司情况总结 - Verve Therapeutics是一家生物技术公司,专注于开发基因编辑疗法 [1] - 公司的主要产品是VERVE-101,这是一种实验性的基因编辑药物 [2] - 公司在2022年8月9日至2024年4月1日期间存在证券欺诈行为 [1][2] - 公司未充分披露Heart-1 Phase 1b临床试验停止的具体情况 [2] - 公司夸大了其专有脂质纳米颗粒递送系统的潜在利益 [2] 行业情况总结 - 生物技术行业是一个高风险高收益的行业,需要密切关注公司的临床试验进展和披露情况 [1][2] - 投资者需要谨慎评估公司的技术优势和产品前景,避免被夸大的宣传所误导 [2]

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=103177&from=3 CLASS PERI ...

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a "clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines." For more information, ...

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. ("Verve Therapeutics" or the "Company") (NASDAQ: VERV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Verve Therapeutics investors who were adversely affected by alleged securities fraud between August 9, 2022 and April 1, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1 ...

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=102405&from=4 CLASS PERIOD: ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Verve between August 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- 9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIR ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=101872&from=4 CLASS PERIOD: ...

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. ("Verve Therapeutics" or the "Company") (NASDAQ: VERV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Verve Therapeutics investors who were adversely affected by alleged securities fraud between August 9, 2022 and April 1, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1 ...

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=101235&from=3 CLASS PERI ...

SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of publicly traded Verve Therapeutics, Inc. (NASDAQ: VERV) ("Verve" or the "Company") securities between August 9, 2022 and April 1, 2024, inclusive (the "Class Period"), charging the Company and certain senior executives with violations of the federal securities laws (collectively, "Defendants"). Verve investors have until October 28, 2024 to seek appointment as lead plaintiff of the Ver ...